AN2 Therapeutics (ANTX) vs Faeth Therapeutics (FTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed Faeth Therapeutics (FTH) over the past year, gaining 366.1% versus a loss of 9.6%. Faeth Therapeutics is the larger company by market cap ($203.7 million vs $192.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | FTH |
|---|---|---|
| Share price | $5.08 | $7.88 |
| Market cap | $192.75M | $203.65M |
| 1-day change | -2.68% | -9.32% |
| YTD return | +345.61% | -26.15% |
| 1-year return | +366.06% | -9.64% |
| 5-year return | — | -94.96% |
| EPS (TTM) | $-0.91 | $-22.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-35.17M | $-21.09M |
| 52-week high | $7.19 | $42.14 |
| 52-week low | $1.00 | $7.45 |
| Distance from 52-week high | -29.35% | -81.30% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +77.17% | +612.56% |
| Average volume | 289.29K | 500.25K |
| Shares outstanding | 37.94M | 25.84M |
| Employees | 21 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed FTH by 375.7 percentage points over the past year.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Faeth Therapeutics
FTH stock →Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
ANTX vs FTH FAQ
Which is bigger, AN2 Therapeutics or Faeth Therapeutics?
Faeth Therapeutics (FTH) is larger, with a market capitalization of $203.65M compared with $192.75M for AN2 Therapeutics (ANTX).
Which stock has performed better over the past year, ANTX or FTH?
ANTX returned +366.06% over the past 12 months, compared with -9.64% for FTH (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and Faeth Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.